

Subject index

Volume 39 (1998)

Acyclovir resistant HSV; Anti-herpes compound; *Echinacea purpurea*; Phytochemical **39**, 55

AIDS; Antiviral agents; Experimental therapeutics; Reverse transcriptase **39**, 101

Anti-herpes compound; Acyclovir resistant HSV; *Echinacea purpurea*; Phytochemical **39**, 55

Anti-herpesvirus activity; 4'-Thioarabinosyl purine nucleosides; 4'-Thioarabinosyl uracil nucleosides; HCMV; HCMV isolates **39**, 129

Anti-HIV-1 activity; CD26; RANTES; CCR5 **39**, 175

Antiviral agents; AIDS; Experimental therapeutics; Reverse transcriptase **39**, 101

Antiviral effect; Apoptosis; Influenza virus; Thujaplicin–metal chelates **39**, 89

Antiviral; ELISA; Herpes simplex; Ribonucleotide reductase; Synergy **39**, 35

Antiviral; Protease inhibitors; HIV therapy; Resistance; Genotypic patterns in resistance **39**, 1

Antivirals; Chemotherapy; Immunoglobulins; Respiratory disease; Ribavirin; RSV **39**, 63

Apoptosis; Antiviral effect; Influenza virus; Thujaplicin–metal chelates **39**, 89

Biflavanoid; Combination therapy; Hepatitis B virus; Natural product; Non-nucleoside antiviral agent **39**, 81

Binding; Fusion; Sendai virus; Viral envelope proteins; Protein mobility **39**, 113

CCR5; CD26; RANTES; Anti-HIV-1 activity **39**, 175

CD38; CD45RA; CD62L; Flow cytometry; HIV-1 **39**, 163

CD62L; CD38; CD45RA; Flow cytometry; HIV-1 **39**, 163

CD45RA; CD38; CD62L; Flow cytometry; HIV-1 **39**, 163

CD26; RANTES; Anti-HIV-1 activity; CCR5 **39**, 175

Chemotherapy; Antivirals; Immunoglobulins; Respiratory disease; Ribavirin; RSV **39**, 63

Combination therapy; Biflavanoid; Hepatitis B virus; Natural product; Non-nucleoside antiviral agent **39**, 81

Cytomegalovirus; Ganciclovir; Dose–response; SCID mice **39**, 189

Diagnosis; Human cytomegalovirus; Treatment; Prophylaxis **39**, 141

Dose–response; Ganciclovir; Cytomegalovirus; SCID mice **39**, 189

Echinacea purpurea; Acyclovir resistant HSV; Anti-herpes compound; Phytochemical **39**, 55

ELISA; Antiviral; Herpes simplex; Ribonucleotide reductase; Synergy **39**, 35

Experimental therapeutics; AIDS; Antiviral agents; Reverse transcriptase **39**, 101

Flow cytometry; CD38; CD45RA; CD62L; HIV-1 **39**, 163

Fusion; Binding; Sendai virus; Viral envelope proteins; Protein mobility **39**, 113

Ganciclovir; Cytomegalovirus; Dose–response; SCID mice **39**, 189

Genotype; HIV; Zidovudine 39, 47

Genotypic patterns in resistance; Protease inhibitors; HIV therapy; Resistance; Antiviral 39, 1

HCMV; Anti-herpesvirus activity; 4'-Thioarabinosyl purine nucleosides; 4'-Thioarabinosyl uracil nucleosides; HCMV isolates 39, 129

HCMV isolates; Anti-herpesvirus activity; 4'-Thioarabinosyl purine nucleosides; 4'-Thioarabinosyl uracil nucleosides; HCMV 39, 129

Hepatitis B virus; Biflavanoid; Combination therapy; Natural product; Non-nucleoside antiviral agent 39, 81

Herbal extract; *Rhus javanica*; Prophylaxis; Herpes simplex virus; Recurrent genital herpes 39, 25

Herpes simplex; Antiviral; ELISA; Ribonucleotide reductase; Synergy 39, 35

Herpes simplex virus; *Rhus javanica*; Prophylaxis; Recurrent genital herpes; Herbal extract 39, 25

HIV-1; CD38; CD45RA; CD62L; Flow cytometry 39, 163

HIV therapy; Protease inhibitors; Resistance; Antiviral; Genotypic patterns in resistance 39, 1

HIV; Zidovudine; Genotype 39, 47

Human cytomegalovirus; Diagnosis; Treatment; Prophylaxis 39, 141

Immunoglobulins; Antivirals; Chemotherapy; Respiratory disease; Ribavirin; RSV 39, 63

Influenza virus; Antiviral effect; Apoptosis; Thujaplicin–metal chelates 39, 89

Natural product; Biflavanoid; Combination therapy; Hepatitis B virus; Non-nucleoside antiviral agent 39, 81

Non-nucleoside antiviral agent; Biflavanoid; Combination therapy; Hepatitis B virus; Natural product 39, 81

Phytochemical; Acyclovir resistant HSV; Anti-herpes compound; *Echinacea purpurea* 39, 55

Prophylaxis; Human cytomegalovirus; Diagnosis; Treatment 39, 141

Prophylaxis; *Rhus javanica*; Herpes simplex virus; Recurrent genital herpes; Herbal extract 39, 25

Protease inhibitors; HIV therapy; Resistance; Antiviral; Genotypic patterns in resistance 39, 1

Protein mobility; Binding; Fusion; Sendai virus; Viral envelope proteins 39, 113

RANTES; CD26; Anti-HIV-1 activity; CCR5 39, 175

Recurrent genital herpes; *Rhus javanica*; Prophylaxis; Herpes simplex virus; Herbal extract 39, 25

Resistance; Protease inhibitors; HIV therapy; Antiviral; Genotypic patterns in resistance 39, 1

Respiratory disease; Antivirals; Chemotherapy; Immunoglobulins; Ribavirin; RSV 39, 63

Reverse transcriptase; AIDS; Antiviral agents; Experimental therapeutics 39, 101

Rhus javanica; Prophylaxis; Herpes simplex virus; Recurrent genital herpes; Herbal extract 39, 25

Ribavirin; Antivirals; Chemotherapy; Immunoglobulins; Respiratory disease; RSV 39, 63

Ribonucleotide reductase; Antiviral; ELISA; Herpes simplex; Synergy 39, 35

RSV; Antivirals; Chemotherapy; Immunoglobulins; Respiratory disease; Ribavirin 39, 63

SCID mice; Ganciclovir; Cytomegalovirus; Dose–response 39, 189

Sendai virus; Binding; Fusion; Viral envelope proteins; Protein mobility 39, 113

Synergy; Antiviral; ELISA; Herpes simplex; Ribonucleotide reductase 39, 35

4'-Thioarabinosyl purine nucleosides; Anti-herpesvirus activity; 4'-Thioarabinosyl uracil nucleosides; HCMV; HCMV isolates 39, 129

4'-Thioarabinosyl uracil nucleosides; Anti-herpesvirus activity; 4'-Thioarabinosyl purine nucleosides; HCMV; HCMV isolates 39, 129

Thujaplicin–metal chelates; Antiviral effect; Apoptosis; Influenza virus 39, 89

Treatment; Human cytomegalovirus; Diagnosis; Prophylaxis 39, 141

Viral envelope proteins; Binding; Fusion; Sendai virus; Protein mobility 39, 113

Zidovudine; HIV; Genotype 39, 47